CircNova, Inc. is a start-up biotechnology company that leverages our unique AI NovaEngine™ to generate, analyze and identify circular RNA for therapeutic development.
Our experts are focused on non-coding RNA (ncRNA) with many mechanisms of action against undruggable disease targets for major unmet clinical needs.
CircNova is developing a robust IP portfolio for development of CircRNA therapeutics.
At CircNova we are driven by our passion to innovate, discover and lead the development of life-changing RNA based therapies.
We aspire to become an industry leader, offering partners and patients new solutions to previously undruggable targets that lead to better quality of life.
We realize our aspiration through investment in continuous AI learning activities, novel data generation and NovaEngine™ pipeline growth.
Key partnerships and collaborations with top research institutions will increase our value through innovative engagement and cutting-edge discoveries.
Our culture is built upon the collective strength of our diversity, expertise and receptivity as founders.
We wish to provide our shareholders and directors with a shared experience of inclusivity, in addition to a superior financial performance and future.